remain posit solid result along major surpris relat prior
period develop indic continu deliv solid execut encourag
commentari regard lower cost trend expect set stage posit
result rest group rais estim slightli reflect revis
remain posit share believ result continu reflect
compani domin market share health plan busi first-mov advantag
close integr healthcar servic busi particular encourag
manag focu use technolog engag member whether
consum digit health platform ralli regist user use
value-bas arrang connect incent across care continuum
consum provid level integr uhc optum
enabl compani succeed payment model increasingli shift toward value-bas
reimburs believ capabl enhanc core offer
enabl grow least in-lin market health plan busi potenti
exceed industri averag growth rate notabl medicar advantag
result benefit net posit reserv develop --
favor develop relat neg develop relat
neg pyd unrel medic cost accord compani
instead driven combin sever small item includ incent payment
provid coordin benefit medicaid note benefit
favor pyd major due favor true up unh
exit individu exchang busi ex-th impact exchang suspect
favor pyd would closer zero intra-year posit develop could
relat medic cost trend outlook improv quarter compani
indic expect medic cost trend slightli midpoint
bp guidanc rang view posit rest manag care group
set start report next week
manag commentari initi relat drug price indic
us well posit succeed chang environ fact
optumrx retent rate expect rang top new win indic
messag drive net healthcar cost reson market
compani given number estim level rebat retain
similar lower esrx report believ
rebat retent like lower peer given ctrx legaci
pleas see page report import disclosur
posit share believ compani domin market share
health plan busi first-mov advantag close integr
healthcar servic busi provid compani competit advantag rel
peer group expect continu grow least line market
health plan busi potenti exceed industri averag growth rate
notabl medicar advantag howev believ real growth stori lie within
compani optum segment optum grown aggreg oper earn
approxim accord project level integr
uhc optum enabl compani succeed payment model
close davita medic group
expect year-end
medicar advantag enrol
repres
commerci ex-hif better
expect
medicaid ex-hif better
better expect growth medicaid
medicaid ex-hif membership
unitedhealth group incorpor diversifi health well-b compani
oper two segment unitedhealthcar uhc includ unitedhealthcar
commun state unitedhealthcar intern optum includ
optumhealth optuminsight optumrx
mani might focus introduct scale pos rebat
think introduct step-edit part could bigger long-term opportun
tie busi found manag comment regard two
specialti pharmaci busi acquir quarter interest particular
note oncolog focu well behavior health see
step-edit part within big impact right see potenti
road competit increas expect biosimilar rituxan time
humira note biosimilar alreadi market
herceptin see acquisit like part long-term strategi increas
expertis oncolog pace biosimilar launch
updat model reflect modest chang quarter full year outlook
mostli line expect note could addit minor chang
publish revis adjust ep project slightli lower
full year project increas
increas opex ratio project bp compani indic
acceler invest spend believ major
addit invest incorpor run-rate spend expect compani
like maintain abil flex certain spend given return
hif lower ex-hif tax rate project reflect
updat view compani full year effect tax rate adjust ep
project remain expect meaning revis follow
annual investor day novemb price target unchang
million except per-shar data
cowen compani estim
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per year end decemb cowen
million except per-shar data
compani report cowen compani
oper loss ratio chang y/ycost product oper tax rate tax earn attribut non-controlling incom common amort expens share outstand fulli net chang year-over-year oper incom common end decemb cowen
million except per-shar data
compani report cowen compani
oper loss ratio loss ratio product product oper revenue oper oper ebitda oper tax rate tax earn attribut non-controlling incom common adjust intang amort expens effect intang amort share outstand fulli net chang year-over-yearpremium revenu cowen
million
compani report cowen compani
asset receiv incom tax current equip net acquir intang asset liabilitiesmed cost payabl accru polici paper current debt less current non-controlling equitycommon stock issu paid-in comp non-controlling sharehold liab liquid ratio current sale claim payabl premium premium structur long-term solvenc ratio return invest capit averag total asset averag stockhold equiti end decemb cowen
million
compani report cowen compani
 incom tax compens chang oper item account cost payabl polici flow oper secur paid acquisit net cash equip capit common stock issuanc foreign currenc rate chang cash cash increas decreas end decemb cowen
million
compani report cowen compani
 incom tax compens chang oper item account cost payabl polici oper paid acquisit net cash equip capit invest common stock long-term proce commerci paper issuanc long-term fund financ foreign currenc rate chang cash cash increas decreas end decemb cowen
valu manag care stock use pe multipl forward earn manag care
sector trade averag forward year earn past year
peak trough troubl econom time
frame given reform-rel multi-year top-lin growth prospect believ sector
trade high end recent histor valuat
success individu public exchang remain consider question mark
head third year program final year two three premium
stabil program reinsur risk corridor although exchang profit
expect improv expect continu money lose enterpris
industri particip receipt risk corridor payment remain potenti threat
success compani reli receiv medicar advantag payment
reduct includ potenti introduct new risk adjust model could
reduc futur medicar advantag margin growth prospect rel expect
gener medicaid payment expans popul gener
howev mount evid state like reduc payment level
medic cost trend mute past year uptick underli
medic cost may difficult predict product price within commerci
becom largest employ owned/affili physician countri via
acquisit partnership optumhealth sub-seg pursu
integr care deliveri model optumhealth sub-seg includ
provid partnership ownership past align incent particularli rise
trend declin payment environ proven difficult furthermor initi
result optumcar shown promis certain market unclear whether
strategi scalabl success lower cost long term unabl
appropri align incent encourag provid take risk patient
popul compani determin strategi costli gener
suffici roi risk stuck larg number capit intens asset may
difficult divest
